Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Hepatitis B and C

  • Chapter
  • First Online:
Sexually Transmitted Infections in HIV-Infected Adults and Special Populations

  • 663 Accesses

Abstract

Coinfection with human immunodeficiency virus (HIV) and hepatitis C (HCV) and/or hepatitis B virus (HBV) is not uncommon as these viruses share transmission routes. With the improved survival of HIV-infected patients due to antiretroviral treatment (ART), liver disease secondary to viral hepatitis has emerged as an important cause of morbidity and mortality in this population. Therefore, screening for and monitoring these infections are an important aspect of HIV care. The interactions between HIV disease and viral hepatitis, and between the drugs required to treat these entities, pose unique challenges to the management of HBV and HCV in HIV-coinfected patients. Great progress has been made in the treatment of HBV and HCV, resulting in improved outcomes, but acute infections continue to fuel the epidemics of HIV and viral hepatitis coinfections, especially among men who have sex with men (MSM).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Joshi D, O’Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011;377:1198–209.

    Article  PubMed  Google Scholar 

  2. Thio C, Seaberg E, Skolasky R Jr, Phair J, Visscher B, Muñoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet. 2002;360:1921–6.

    Article  PubMed  Google Scholar 

  3. Salmon-Ceron D, Lewden C, Morlat P, Bévilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42(6):799–805.

    Article  CAS  PubMed  Google Scholar 

  4. Hoffmann CJ, Seaberg EC, Young S, Witt MD, D’Acunto K, Phair J, et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS. 2009;23:1881–9.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Ioannou GN1, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology. 2013;57(1):249–57.

    Google Scholar 

  6. Chun HM, Roediger MP, Hullsiek KH, Thio CL, Agan BK, Bradley WP, et al. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis. 2012;205(2):185–93.

    Article  PubMed  Google Scholar 

  7. Kovari H, Ledergerber B, Cavassini M, Ambrosioni J, Bregenzer A, Stöckle M, et al. High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. J Hepatol. 2015;63(3):573–80.

    Article  PubMed  Google Scholar 

  8. Grint D, Peters L, Rockstroh JK, Rakmanova A, Trofimova T, Lacombe K, et al. Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. AIDS. 2015;29(10):1205–15.

    Article  CAS  PubMed  Google Scholar 

  9. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed 2/3/2016.

  10. Gorgos L. Sexual transmission of viral hepatitis. Infect Dis Clin North Am. 2013;27(4):811–36.

    Article  PubMed  Google Scholar 

  11. MacKellar DA, Valleroy LA, Secura GM, McFarland W, Shehan D, Ford W, et al. Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men. Am J Public Health. 2001;91:965–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Jansen K, Thamm M, Bock CT, Scheufele R, Kücherer C, Muenstermann D, et al. High prevalence and high incidence of coinfection with hepatitis B, hepatitis C, and syphilis and low rate of effective vaccination against hepatitis B in HIV-positive men who have sex with men with known date of HIV seroconversion in Germany. PLoS ONE. 2015;10(11):e0142515.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Chonwattana W, Raengsakulrach B, Holtz TH, Wasinrapee P, Tongtoyai J, Chaikummao S, et al. Hepatitis B vaccination uptake and correlates of serologic response among HIV-infected and uninfected men who have sex with men (MSM) in Bangkok, Thailand. Vaccine. 2016;34(17):2044–50.

    Article  CAS  PubMed  Google Scholar 

  14. Kojima Y, Kawahata T, Mori H, Furubayashi K, Taniguchi Y, Itoda I, Komano J. Identification of novel recombinant forms of hepatitis B virus generated from genotypes Ae and G in HIV-1-positive Japanese men who have sex with men. AIDS Res Hum Retroviruses. 2015;31(7):760–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59(1):318–27.

    Article  PubMed  Google Scholar 

  16. Goeser F, Glässner A, Kokordelis P, Wolter F, Lutz P, Kaczmarek DJ, et al. HIV mono-infection is associated with an impaired anti-hepatitis C virus activity of natural killer cells. AIDS. 2016;30(3):355–63.

    CAS  PubMed  Google Scholar 

  17. Kokordelis P, Krämer B, Boesecke C, Voigt E, Ingiliz P, Glässner A, et al. CD3(+)CD56(+) natural killer-like T cells display anti-HCV Activity but are functionally impaired in HIV(+) patients with acute hepatitis C. J Acquir Immune Defic Syndr. 2015;70(4):338–46.

    Article  CAS  PubMed  Google Scholar 

  18. Seaberg EC, Witt MD, Jacobson LP, Detels R, Rinaldo CR, Margolick JB, et al. Spontaneous clearance of the hepatitis C virus among men who have sex with men. Clin Infect Dis. 2015;61(9):1381–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Chayama K, Kobayashi M, Tsubota A, Koida I, Arase Y, Saitoh S, et al. Molecular analysis of intraspousal transmission of hepatitis C virus. J Hepatol. 1995; 22:431–9.

    Google Scholar 

  20. Kao JH, Liu CJ, Chen PJ, Chen W, Hsiang SC, Lai MY, et al. Low incidence of hepatitis C virus transmission between spouses: a prospective study. J Gastroenterol Hepatol. 2000;15:391–5.

    Article  CAS  PubMed  Google Scholar 

  21. van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology. 2009;136:1609–17.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Vanhommerig JW, Thomas XV, van der Meer JT, Geskus RB, Bruisten SM, Molenkamp R, et al. Hepatitis C virus (HCV) antibody dynamics following acute HCV infection and reinfection among HIV-infected men who have sex with men. Clin Infect Dis. 2014;59:1678–85.

    Article  CAS  PubMed  Google Scholar 

  23. Thomas XV, Grady BP, Van Der Meer JT, Ho CK, Vanhommerig JW, Rebers SP, et al. Genetic characterization of multiple hepatitis C virus infections following acute infection in HIV-infected men who have sex with men. AIDS. 2015;29(17):2287–95.

    Article  CAS  PubMed  Google Scholar 

  24. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology. 1999;29(4):1306–10.

    Article  CAS  PubMed  Google Scholar 

  25. Zhou J, Dore GJ, Zhang F, Lim PL, Chen YM. Hepatitis B and C virus coinfection in the TREAT Asia HIV observational database. J Gastroenterol Hepatol. 2007;22:1510–8.

    Google Scholar 

  26. Alter MJ. Epidemiology of viral hepatitis and HIV coinfection. J Hepitol. 2006;44(1 Suppl):S6–9.

    Article  Google Scholar 

  27. Falade-Nwulia O, Seaberg EC, Snider AE, Rinaldo CR, Phair J, Witt MD, et al. Incident hepatitis B virus infection in HIV-Infected and HIV-uninfected men who have sex with men from pre-HAART to HAART periods: a cohort study. Ann Intern Med. 2015;163(9):673–80.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Spradling PR, Richardson JT, Buchacz K, Moorman AC, Brooks JT, HIV Outpatient Study (HOPS) Investigators. Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996–2007. J Viral Hepat. 2010;17(12):879–86.

    Google Scholar 

  29. Chun HM, Fieberg AM, Hullsiek KH, Lifson AR, Crum-Cianflone NF, Weintrob AC, et al. Epidemiology of hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years. Clin Infect Dis. 2010;50(3):426–36.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Staples CT, Jr., Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of co-infection on survival. Clin Infect Dis. 1999;29(1):150–4 (An official publication of the Infectious Diseases Society of America).

    Google Scholar 

  31. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34(6):831–7 (An official publication of the Infectious Diseases Society of America).

    Article  PubMed  Google Scholar 

  32. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42.

    Article  PubMed  Google Scholar 

  33. Sulkowski MS. HCV-HIV co-infected patients: no longer a ‘special’ population? Liver Int. 2016;36(Suppl. S1):43–6.

    Google Scholar 

  34. Paintsil E, He H, Peters C, Lindenbach BD, Heimer R. Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J Infect Dis. 2010;202(7):984–90.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Lissen E, Alter HJ, Abad MA, Torres Y, Pérez-Romero M, Leal M, et al. Hepatitis C virus infection among sexually promiscuous groups and the heterosexual partners of hepatitis C virus infected index cases. Eur J Clin Microbiol Infect Dis. 1993;12(11):827–31.

    Article  CAS  PubMed  Google Scholar 

  36. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, Fisher M, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS. 2007;21(8):983–91.

    Article  PubMed  Google Scholar 

  37. van de Laar TJ, van der Bij AK, Prins M, Bruisten SM, Brinkman K, Ruys TA, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis. 2007;196(2):230–8.

    Article  PubMed  Google Scholar 

  38. van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS. 2010;24(12):1799–812.

    Article  PubMed  Google Scholar 

  39. Rauch A, Rickenbach M, Weber R, Hirschel B, Tarr PE, Bucher HC, et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis. 2005;41(3):395–402 (An official publication of the Infectious Diseases Society of America).

    Article  PubMed  Google Scholar 

  40. Stolte IG, Dukers NH, Geskus RB, Coutinho RA, de Wit JB. Homosexual men change to risky sex when perceiving less threat of HIV/AIDS since availability of highly active antiretroviral therapy: a longitudinal study. AIDS. 2004;18(2):303–9.

    Article  PubMed  Google Scholar 

  41. Taylor LE, Holubar M, Wu K, Bosch RJ, Wyles DL, Davis JA, et al. Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. Clin Infect Dis. 2011;52(6):812–8 (An official publication of the Infectious Diseases Society of America).

    Article  PubMed  PubMed Central  Google Scholar 

  42. Hill AM, Simmons B, Saleem J, Cooke G. Five-year risk of late relapse or reinfection with hepatitis C after sustained virological response: meta-analysis of 49 studies in 8534 patients. CROI 2015; February 23–26, 2015. Seattle, Washington. Abstract number 654.

    Google Scholar 

  43. Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005;192(11):1880–9.

    Article  PubMed  Google Scholar 

  44. Centers for Diseases Control and prevention. Viral Hepatitis—Hepatitis B Information. http://www.cdc.gov/hepatitis/hbv/

  45. Vogel M, Page E, Boesecke C, Reiberger T, Schwarze-Zander C, Mauss S, et al. Liver fibrosis progression after acute hepatitis C virus infection in HIV-positive individuals. Clin Infect Dis. 2012;54(4):556–9.

    Article  PubMed  Google Scholar 

  46. Butt AA, Yan P, Lo Re V 3rd, Rimland D, Goetz MB, Leaf D, et al. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med. 2015;175(2):178–85.

    Google Scholar 

  47. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562–9.

    Article  CAS  PubMed  Google Scholar 

  48. Kramer JR, Kowalkowski MA, Duan Z, Chiao EY. The effect of HIV viral control on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV coinfection. J Acquir Immune Defic Syndr. 2015;68(4):456–62.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Villar LM, Cruz HM, Barbosa JR, Bezerra CS, Portilho MM, Scalioni LP. Update on hepatitis B and C virus diagnosis. World J Virol. 2015;4(4):323–42.

    PubMed  PubMed Central  Google Scholar 

  50. Barbour S, Bachmann L, Núñez M. Transient hepatitis B surface antigenemia after hepatitis B virus vaccine in an HIV-infected patient. AIDS Res Hum Retroviruses. 2013;29(4):639–40.

    Article  CAS  PubMed  Google Scholar 

  51. Lok ASF, McMahon BJ. AASLD practice guidelines. Chronic hepatitis B: update 2009. Hepatology. 2009;50:1–36.

    Google Scholar 

  52. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83.

    Article  PubMed  Google Scholar 

  53. Hearn B, Chasan R, Bichoupan K, Suprun M, Bagiella E, Dieterich DT, et al. Low adherence of HIV providers to practice guidelines for hepatocellular carcinoma screening in HIV/hepatitis B coinfection. Clin Infect Dis. 2015;61(11):1742–8.

    PubMed  PubMed Central  Google Scholar 

  54. Shores NJ, Maida I, Soriano V, Núnez M. Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. J Hepatol. 2008;49:323–8.

    Article  PubMed  Google Scholar 

  55. Freiman JM, Huang W, White LF, Geng EH, Hurt CB, Taylor LE, et al. Current practices of screening for incident hepatitis C virus (HCV) infection among HIV-infected, HCV-uninfected individuals in primary care. Clin Infect Dis. 2014;59:1686–93.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Reiberger T. Acute hepatitis C virus infection in HIV-infected men who have sex with men: should we change our screening practice? Clin Infect Dis. 2014;59(12):1694–5.

    Article  PubMed  Google Scholar 

  57. Whitaker JA, Rouphael NG, Edupuganti S, Lai L, Mulligan MJ. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet. 2012;12(12):966–76.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Piroth L, Launay O, Michel ML, Bourredjem A, Miailhes P, Ajana F, et al. Vaccination against hepatitis B virus in HIV-1 infected patients with isolated anti-HBc: the ANRS HB EP03 CISOVAC prospective study. J Infect Dis. 2016 Jan 14. pii: jiw011. [Epub ahead of print] PMID: 26768256.

    Google Scholar 

  59. Mendes-Corrêa M, Núñez M. Management of HIV and hepatitis virus coinfection. Expert Opin Pharmacother. 2010;11:2497–516.

    Article  PubMed  Google Scholar 

  60. Núñez M, Ramos B, Díaz-Pollán B, Camino N, Martín-Carbonero L, Barreiro P, et al. Virological outcome of chronic hepatitis B virus infection in HIV coinfected patients receiving anti-HBV active antiretroviral therapy. AIDS Res Hum Retroviruses. 2006;22:842–8.

    Article  PubMed  Google Scholar 

  61. Lee T, Núñez M. Longer duration of HBV-active antiretroviral therapy is linked to favorable virological outcome in HIV-HBV co-infected patients. HIV Clin Trials. 2009;10:153–9.

    Article  PubMed  Google Scholar 

  62. Thio CL, Smeaton L, Hollabaugh K, Saulynas M, Hwang H, Saravanan S, et al. Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks. AIDS. 2015;29(10):1173–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Huang AJ, Núñez M. Outcomes in HIV/HBV-coinfected patients in the tenofovir era are greatly affected by immune suppression. J Int Assoc Provid AIDS Care. 2015;14(4):360–8.

    Article  PubMed  Google Scholar 

  64. Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, Kuzushita N, et al. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLoS ONE. 2013;8(7):e68152.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Dore GJ, Soriano V, Rockstroh J, Kupfer B, Tedaldi E, Peters L, et al. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-co-infected patients following antiretroviral therapy interruption. AIDS. 2010;24(6):857–65.

    Article  PubMed  PubMed Central  Google Scholar 

  66. de Vries-Sluijs TE, Reijnders JG, Hansen BE, Zaaijer HL, Prins JM, Pas SD, et al. Longterm therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology. 2010;139:1934–41.

    Article  PubMed  Google Scholar 

  67. Mendes-Correa MC, Pinho JR, Gomes-Gouvea MS, da Silva AC, Guastini CF, Martins LG, et al. Predictors of HBeAg status and hepatitis B viraemia in HIV infected patients with chronic hepatitis B in the HAART era in Brazil. BMC Infect Dis. 2011;11:247.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Miailhes P, Trabaud MA, Pradat P, Lebouché B, Chevallier M, Chevallier P, et al. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis. 2007;45:624–32.

    Article  PubMed  Google Scholar 

  69. Sheng WH, Kao JH, Chen PJ, Huang LM, Chang SY, Sun HY, et al. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2007;45:1221–9.

    Article  PubMed  Google Scholar 

  70. Matthews GV, Seaberg E, Dore GJ, Bowden S, Lewin SR, Sasadeusz J, et al. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS. 2009;23:1707–15.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Boyd A, Gozlan J, Miailhes P, Lascoux-Combe C, Cam MS, Rougier H, et al. Rates and determinants of hepatitis B ‘e’ antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus. AIDS. 2015;29(15):1963–73.

    Article  CAS  PubMed  Google Scholar 

  72. Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomized, active-controlled, multicenter, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16(1):43–52.

    Article  CAS  PubMed  Google Scholar 

  73. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS. 2004;18:2039–45.

    Article  PubMed  Google Scholar 

  74. Stockdale AJ, Phillips RO, Beloukas A, Appiah LT, Chadwick D, Bhagani S, Bonnett L, et al. Liver Fibrosis by transient elastography and virologic outcomes after introduction of tenofovir in lamivudine-experienced adults with HIV and hepatitis B virus coinfection in Ghana. Clin Infect Dis. 2015;61(6):883–91.

    Article  CAS  PubMed  Google Scholar 

  75. Sulkowski MS. Management of acute and chronic HCV infection in persons with HIV coinfection. J Hepatol. 2014;61:S108–19.

    Article  CAS  PubMed  Google Scholar 

  76. American Association for the Study of Liver Diseases/Infectious Diseases Society of America. Hepatitis C guidance: recommendations for testing, managing, and treating adults infected with hepatitis C virus. Available at http://www.hcvguidelines.org/. Accessed 20 Feb 2016.

  77. Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313(12):1232–9.

    Article  CAS  PubMed  Google Scholar 

  78. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and Sofosbuvir for HCV in patients Co-infected with HIV-1. N Engl J Med. 2015;373:705–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313:1223–31.

    Article  CAS  PubMed  Google Scholar 

  80. Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312(4):353–61.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus sofosbuvir for HCV in patients co-infected with HIV-1. N Engl J Med. 2015;373:714–25.

    Article  CAS  PubMed  Google Scholar 

  82. Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1087–97.

    Article  CAS  PubMed  Google Scholar 

  83. Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2(8):e319–27. Erratum in: Lancet HIV. 2015;2(8):e316. Lancet HIV. 2015;2(10):e416.

    Google Scholar 

  84. Collins JM, Raphael KL, Terry C, Cartwright EJ, Pillai A, Anania FA, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis. 2015;61(8):1304–6.

    Article  CAS  PubMed  Google Scholar 

  85. Takayama H, Sato T, Ikeda F, Fujiki S. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res. 2015. doi:10.1111/hepr.12578 [Epub ahead of print].

  86. Balagopal A, Thio CL. Another call to cure hepatitis B. Clin Infect Dis. 2015;61:1307–9.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Wake Forest University Health Sciences, 1 Medical Center Blvd, Winston-Salem, NC, 27157, USA

    Joseph Carlin

  2. Department of Infectious Diseases, Sao Paulo University Medical School, Rua Andre Dreyfus n. 274, São Paulo, SP, 01252010, Brazil

    Maria Cassia Mendes-Correa

  3. Department of Internal Medicine, Section on Infectious Diseases, Wake Forest University Health Sciences, Medical Center Boulevard, Winston-Salem, NC, 27157, USA

    Marina Núñez

Authors
  1. Joseph Carlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Cassia Mendes-Correa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marina Núñez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marina Núñez .

Editor information

Editors and Affiliations

  1. Division of Infectious Diseases, Wake Forest University Health Sciences, Winston-Salem, North Carolina, USA

    Laura Hinkle Bachmann

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Carlin, J., Mendes-Correa, M.C., Núñez, M. (2017). Hepatitis B and C. In: Bachmann, L. (eds) Sexually Transmitted Infections in HIV-Infected Adults and Special Populations. Springer, Cham. https://doi.org/10.1007/978-3-319-56694-8_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56694-8_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56692-4

  • Online ISBN: 978-3-319-56694-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation